Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?
Vatche G. Agopian, Ju Dong Yang, Yazhen Zhu, Sungyong You, Hsian‐Rong Tseng – 5 February 2022
ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?
Mazen Noureddin, Manal F. Abdelmalek – 5 February 2022
Measure twice, cut once
Sean Koppe – 4 February 2022
Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma
Youngsic Jeon, So Mee Kwon, Hyungjin Rhee, Jeong Eun Yoo, Taek Chung, Hyun Goo Woo, Young Nyun Park – 4 February 2022
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992–2018
Christian S. Alvarez, Jessica L. Petrick, Dominick Parisi, Brian J. McMahon, Barry I. Graubard, Katherine A. McGlynn – 4 February 2022
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R. Galle, Philipp S. Wild, Karl J. Lackner, Jörn M. Schattenberg – 4 February 2022 – The prevalence of liver disease, and especially of advanced liver fibrosis, in the German population is poorly defined. The aim of the study was to explore liver enzymes and surrogate scores of hepatic steatosis and advanced hepatic fibrosis in a population‐based cohort study in Germany.
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992–2018
Christian S. Alvarez, Jessica L. Petrick, Dominick Parisi, Brian J. McMahon, Barry I. Graubard, Katherine A. McGlynn – 4 February 2022
Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?
Zoe N. Memel, Jeffrey Wang, Kathleen E. Corey – 2 February 2022
Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study
Xuemei Tao, Youfei Zhao, Lin Chen, Minghui Zeng, Yuqiang Mi, Liang Xu – 2 February 2022
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?
Alberto Zanetto, Elena Campello, Luca Spiezia, Patrizia Burra, Paolo Simioni, Marco Senzolo – 2 February 2022